{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:02:12Z","timestamp":1785466932112,"version":"3.56.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Antimicrob. Chemother."],"DOI":"10.1093\/jac\/dkw480","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T02:56:19Z","timestamp":1482548179000},"page":"dkw480","source":"Crossref","is-referenced-by-count":8,"title":["The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against<b>\u03b2<\/b>-lactamase-producing Enterobacteriaceae studied in an<i>in vitro<\/i>model of infection"],"prefix":"10.1093","author":[{"given":"Alasdair","family":"MacGowan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Tomaselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bowker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,12,30]]},"reference":[{"key":"2016123018101167000_dkw480v1.1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn320"},{"key":"2016123018101167000_dkw480v1.2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00641-09"},{"key":"2016123018101167000_dkw480v1.3","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05005-11"},{"key":"2016123018101167000_dkw480v1.4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00080-14"},{"key":"2016123018101167000_dkw480v1.5","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv132"},{"key":"2016123018101167000_dkw480v1.6","unstructured":"Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing\u2014Approved Standard M100-S16. CLSI, Wayne, PA, USA, 2005."},{"key":"2016123018101167000_dkw480v1.7","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.suppl_1.5"},{"key":"2016123018101167000_dkw480v1.8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.10.2351"},{"key":"2016123018101167000_dkw480v1.9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1128\/AAC.41.4.721","article-title":"Importance of \u03b2-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam","volume":"41","author":"Lister","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2016123018101167000_dkw480v1.10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4482-4484.2004"},{"key":"2016123018101167000_dkw480v1.11","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq161"},{"key":"2016123018101167000_dkw480v1.12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00024-11"},{"key":"2016123018101167000_dkw480v1.13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00859-05"},{"key":"2016123018101167000_dkw480v1.14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01269-15"},{"key":"2016123018101167000_dkw480v1.15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2916-2921.2001"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T18:14:04Z","timestamp":1568657644000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkw480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,30]]},"references-count":15,"alternative-id":["10.1093\/jac\/dkw480"],"URL":"https:\/\/doi.org\/10.1093\/jac\/dkw480","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,30]]}}}